

CME

This event has been accredited by the national programme for Continuing Medical Education with the Objective N°3.

Provider: Prex Srl. Event Ref: 75 - 269318-1. Number of Credits: 12,6.

Professions: Medical Doctors, Pharmacists.

Disciplines: Internal Medicine, Infectious Diseases, General Practitioner, Gastroenterology, Haematology, Hospital Pharmacy.

Each participant can only receive the number of credits he/she is entitled to according to his/her actual participation at the event once he/she has completed the evaluation form after the congress.

You may submit your registration on www.prex.it/eventi/masterclass

Registration is subject to availability.



HEPATITIS MASTERCLASS

2019

SCIENTIFIC COORDINATOR

Pietro Lampertico | *Milano*

SPEAKERS AND MODERATORS

Alessandra Bandera | *Milano*

Sherrie Bhoori | *Milano*

Roberta D'Ambrosio | *Milano*

Elisabetta Degasperì | *Milano*

Maria Francesca Donato | *Milano*

Massimo Alberto Iavarone | *Milano*

Federica Invernizzi | *Milano*

Pietro Invernizzi | *Monza*

Agarwal Kosh | *London*

Vincenzo La Mura | *Milano*

Alessandro Loglio | *Milano*

Vincenzo Mazzaferro | *Milano*

Massimo Primignani | *Milano*

Angelo Sangiovanni | *Milano*

Filippo Schepis | *Modena*

Heiner Wedemeyer | *Essen*

SCIENTIFIC COORDINATOR:

Prof. Pietro Lampertico


**26-27
SEPTEMBER 2019**

Congress venue:

MILANO

Le Village by CA Milano
Corso di Porta Romana, 61

With the unconditional
support by





RATIONALE

The recent improvement in diagnostic tools accuracy as well as the availability of new therapeutic strategies against several viral and not viral-related liver diseases have led to significant changes in clinical practice. Moreover, cirrhosis-related complications still remain strong predictors of prognosis, also in those patients achieving a virological response to current anti-HCV and anti-HBV therapies. Therefore, several efforts have been recently made in order to optimize both the diagnostic and therapeutic algorithms of patients affected by HCC and portal hypertension. Finally, we face with growing interest in chronic liver diseases due to changes in epidemiology (i.e. HDV infection, NASH and ASH) and/or availability of new therapeutic compounds (i.e. HDV, NASH, PBC).

The "Hepatitis Masterclass 2019" will represent a unique opportunity to face with novelties in specific Hepatology fields and to discuss with International experts on the impact of new diagnostic and therapeutic strategies in field practice.

PROGRAMME

26 SEPTEMBER 2019 - DAY 1

- 13.20-13.50 Welcome light lunch
- 13.50-14.10 Meeting starts - *Pietro Lampertico*

SESSION 1 – Moderators: *Agarwal Kosh and Roberta D’Ambrosio*

- 14.10-14.30 Current strategies for HCV elimination - *Agarwal Kosh*
- 14.30-14.50 Discussion
- 14.50-15.10 Diagnostic and Therapeutic Pathway 1 - SVR post-DAA and clinical outcomes - *Elisabetta Degasperi*
- 15.10-15.30 Discussion
- 15.30-15.50 New treatment approaches for HBV infection - *Pietro Lampertico*
- 15.50-16.10 Discussion
- 16.10-16.30 New treatment approaches for HDV infection - *Heiner Wedemeyer*
- 16.30-16.50 Discussion
- 16.50-17.10 *Coffee Break*

26 SEPTEMBER 2019 - DAY 1

SESSION 2 – Moderators: *Vincenzo Mazzaferro and Angelo Sangiovanni*

- 17.10-17.30 HCC treatment: advances in surgical treatment - *Vincenzo Mazzaferro*
- 17.30-17.50 Discussion
- 17.50-18.10 HCC: new systemic drugs on the starting blocks - *Massimo Iavarone*
- 18.10-18.30 Discussion
- 18.30-18.50 Diagnostic and Therapeutic Pathway 2 - Immune checkpoint and liver involvement - *Sherrie Bhoori*
- 18.50-19.10 Discussion
- 19.10-19.20 Meeting closes - *Pietro Lampertico*

27 SEPTEMBER 2019 - DAY 2

SESSION 3 – Moderators: *Heiner Wedemeyer and Maria Francesca Donato*

- 08.30-08.50 Liver transplantation 2020: Optimal criteria for enlisting and prioritizing - *Vincenzo Mazzaferro*
- 08.50-09.10 Discussion
- 09.10-09.30 The burden of alcoholic liver disease in the transplant setting - *Agarwal Kosh*
- 09.30-09.50 Discussion
- 09.50-10.10 Diagnostic and Therapeutic Pathway 3 – HDV and autoimmunity - *Alessandro Loglio*
- 10.10-10.40 *Coffee Break*

SESSION 4 – Moderators: *Pietro Lampertico and Massimo Primignani*

- 10.40-11.10 Anticoagulants in cirrhosis: issues and perspectives - *Filippo Schepis*
- 11.10-11.30 Discussion
- 11.30-11.50 Diagnostic and Therapeutic Pathway 4 - TIPS and cirrhosis - *Vincenzo La Mura*
- 11.50-12.10 Discussion
- 12.10-12.30 Diagnostic and Therapeutic Pathway 5 - Acute on Chronic Liver Failure - *Federica Invernizzi*
- 12.30-12.50 Discussion
- 12.50-14.00 *Light Lunch*

SESSION 5 – Moderators: *Pietro Invernizzi and Alessandra Bandera*

- 14.00-14.20 Cirrhosis and sepsis - *Alessandra Bandera*
- 14.20-14.40 Discussion
- 14.40-15.00 New data on PBC treatment - *Pietro Invernizzi*
- 15.00-15.20 Discussion
- 15.20-15.40 Future perspectives for NASH therapy - *Roberta D’Ambrosio*
- 15.40-16.20 Discussion
- 16.20-17.00 Meeting closes - *Pietro Lampertico*
- 17.00 Test CME

HEPATITIS MASTERCLASS

